Endo, Advanz Pharma Partner To Commercialize Xydalba In Canada

Endo International plc (ENDP) said that its subsidiary, Endo Ventures Limited, has reached a definitive agreement with Correvio International Sàrl entity, a subsidiary of Advanz Pharma, to commercialize and distribute on an exclusive basis Xydalba or dalbavancin hydrochloride in Canada.

As per the terms of the deal, Endo Ventures will be responsible for the distribution, sales, marketing, medical affairs, pricing and reimbursement activities in Canada. Endo Venture Limited's affiliate, Paladin Labs, an operating company of Endo International, will perform those activities.

Advanz Pharma will be responsible for supplying the drug. Paladin Labs is targeting to launch the product in 2021. Advanz Pharma will provide additional business updates as and when appropriate.

Xydalba was approved by Health Canada in September 2018 for the treatment of Acute Bacterial Skin and Skin Structure Infections in adults caused by susceptible isolates of gram-positive microorganisms, including methicillin resistant Staphylococcus aureus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors Co. (GM) said its second-quarter results were better than originally expected due to strong pricing and demand, record GM Financial results and improved near-term production from the pull forward of semiconductors from the third quarter. Based on first-half performance and expectations... PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast.
Follow RTT